/
Summary NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ( NRx , the Company , we , us or our ) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTS…
The business is unprofitable at the operating level (-1324.41% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -125.29% to -454.34%, capital efficiency is deteriorating. Negative free cash flow of -$14M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$2M
Net Income (TTM)
-$25M
▼ -13.9% YoY
Op. Margin
-746.58%
ROIC
-2829.29%
▼ -329.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$15M
▼ -32.7% YoY
Op. Cash Flow (TTM)
-$15M
▼ -32.7% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$7M
Continue Research